Home › Compound Library › KPV (Lys-Pro-Val)

KPV (Lys-Pro-Val)

Peptideoral · inferred

C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). Potent anti-inflammatory at nanomolar concentrations via NF-kB and MAPK pathway inhibition. Very short plasma half-life typical of tripeptides (~15 min). Taken orally, SC, or intranasally for gut inflammation and systemic anti-inflammatory effects.

Projected serum levels — 500 mcg (≈ 0.50 mg), once daily

KPV (Lys-Pro-Val)
KPV (Lys-Pro-Val) modeled serum levels, 500 mcg (≈ 0.50 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mcg (≈ 0.50 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.073 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Oral
Model confidence
inferred
Half-life
14 min
Common dose
500 mcg (≈ 0.50 mg)
Suggested maximum
1.5k mcg/day
Reference dose range
250–1.5k mcg (single dose)
Suggested cadence
once daily

Documented interactions

  • moderate
    Melanotan II + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and Melanotan II both push the mc1r and mc3r in the same direction.

  • moderate
    PT-141 (Bremelanotide) + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and PT-141 (Bremelanotide) both push the mc1r and mc3r in the same direction.

  • watch
    Mesalamine / 5-ASA (Lialda/Apriso/Pentasa) + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and Mesalamine / 5-ASA (Lialda/Apriso/Pentasa) both push the nfkb signaling in the same direction.

  • watch
    Milk Thistle (Silymarin / Silybin) + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and Milk Thistle (Silymarin / Silybin) both push the nfkb signaling in the same direction.

  • watch
    MSM (Methylsulfonylmethane) + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and MSM (Methylsulfonylmethane) both push the nfkb signaling in the same direction.

  • watch
    Sulfasalazine (Azulfidine) + KPV (Lys-Pro-Val) Stacked effects

    KPV (Lys-Pro-Val) and Sulfasalazine (Azulfidine) both push the nfkb signaling in the same direction.

Serum checks 7 modeled interaction pairings for kpv (lys-pro-val) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation Dalmasso G et al. · Gastroenterology, 2008 DOI

    Demonstrated KPV is transported into colonocytes via PepT1 transporter, where it inhibits NF-kB activation and reduces intestinal inflammation in colitis models at nanomolar concentrations.

  2. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis Xiao B et al. · Molecular Therapy, 2017 DOI

    Developed HA-functionalized nanoparticles for oral KPV delivery that efficiently targeted inflamed colonic tissue and alleviated ulcerative colitis in mouse models.

  3. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists Lam CW et al. · Molecular and Cellular Endocrinology, 2012 DOI

    Elucidated KPV mechanism showing dose-dependent inhibition of NF-kB via IkappaBalpha stabilization and nuclear import blockade, with anti-inflammatory effects in bronchial epithelium.

3 published studies referenced in the app, each with a plain-language summary.